⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PALI News
Palisade Bio, Inc. Common Stock
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
globenewswire.com
PALI
Form 8-K
sec.gov
PALI
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
globenewswire.com
PALI
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
globenewswire.com
PALI
Form 8-K
sec.gov
PALI
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
globenewswire.com
PALI
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
globenewswire.com
PALI
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
PALI
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
globenewswire.com
PALI
Form 8-K
sec.gov
PALI